Milan, Italy / Ulm, Germany / Warsaw, Poland – August 2018
Exom Group, the Expert Digital CRO and MTZ, a leading early phase Clinical Research Site based in Warsaw, today announced a strategic partnership to revolutionize early phase clinical trials by implementing Genius SUITE EPR™, an innovative multi-modular digital application.
“Especially in early phase clinical trials, when it comes to dose finding, the fast availability of clinical data, through an advanced visualization and data analytics tool (Genius REVEAL™), is crucial for the decision-making process.”, says Dr. Luigi Visani, President and CEO of Exom Group. “By utilizing our newly developed technologies, the clients benefit from an improved and accelerated clinical trial conduct with increased quality and at a very competitive price.” He continued.
With MTZ, Exom Group has found a very experienced partner with more than one and a half decades of experience in clinical trials. Among the key expertise of MTZ is Oncology, Hematology, as well as Immunology and Dermatology. The clinical facilities offer state-of-the-art equipment for early phase clinical trials, as well as 30 beds for overnight stays required in e.g. PK studies.
With this cooperation Exom Group and MTZ aim at reinventing the early phase clinical trial environment, by giving the clients real-time, advance analytics for the early detection of signals and fast decision making. Further they aim at significantly shortening the timelines for early phase or bioequivalence studies.
Exom is a Milan, Italy headquartered CRO, which is committed to the modernization of Clinical Trials through Digital Transformation and Patient Engagement. By combining its expertise across medical, regulatory and operational functions with its proprietary, multi-modular and cloud-based platform Genius SUITE™, Exom improves efficiencies and escalate process speeds while ensuring data quality and costs reduction, from Early Phase to Late & Outcome Studies.
About MTZ Clinical Research
MTZ Clinical Research located downtown Warsaw, Poland, is the Clinical Research Site specialized in early phase clinical trials. Company has performed above 250 clinical trials of which about 80 are BE and 34 of phase I trials including first in human. Company specializes in trials with biological and /or biosimilar medicinal products and offers services from protocol creation, regulatory approval obtaining, through clinical trial conduct to data management and final report preparation. The Company holds ISO 9001:2015 certificate and was subjected to several inspections, including FDA (NAI).
Exom Group Srl
Viale F. Restelli 3/1
20124 Milan (Italy)
Ph. +39 02 36725581
Fax +39 02 36725580